Abstract
Management of immune thrombocytopenia (ITP) is complex requiring communication between
patients and caregivers to establish a mutual understanding of the impact of the patient's
disease on quality of life, the current symptoms and risk of morbidity/mortality and
the goals of therapy. The currently available second-line therapies for ITP provide
potential for management of thrombocytopenia and bleeding symptoms with medical therapy
or surgical intervention potentially offering long-term remission. All therapies are
associated with potential side effects and necessary monitoring or modifications/risks
and careful discussion of these is necessary to determine the optimal therapy for
each patient. This review covers second-line therapies for ITP and discusses the currently
available information on immunomodulatory second-line treatments for ITP.
Keywords
autoimmune disease - platelet - ITP - treatment
